RIGEL (RIGL) EVP granted 7,394 fully vested performance stock options

Rhea-AI Filing Summary

RIGEL PHARMACEUTICALS EVP and Chief Commercial Officer David A. Santos reported a performance-based stock option award covering 7,394 shares of common stock. The option has an exercise price of $22.49 per share and an expiration date of January 29, 2035.

The award was originally granted on January 29, 2025 with a performance-based vesting condition, and it became fully vested on June 17, 2026 when the company determined that the performance metric had been met.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Santos David A

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	7,394	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 7,394 shares (Direct, null)

Footnotes (1)

1. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

Key Figures

Option size: 7,394 shares Exercise price: $22.49 per share Expiration date: January 29, 2035 +1 more

4 metrics

Option size 7,394 shares Underlying common stock in performance-based option

Exercise price $22.49 per share Closing price on Nasdaq on January 29, 2025

Expiration date January 29, 2035 Option term end

Vesting date June 17, 2026 Date performance metric determined met; option fully vested

Key Terms

performance-based condition, performance metric, Section 16, vesting

4 terms

performance-based condition financial

"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares"

performance metric financial

"In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied."

Section 16 regulatory

"this grant was not reportable under Section 16 until the performance metric was satisfied."

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

vesting financial

"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos David A

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$22.49(1)	06/17/2026		A		7,394(1)		(2)	01/29/2035	Common Stock	7,394(1)	$0	7,394	D

Explanation of Responses:

1. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

	/s/ Raymond Furey (Attorney-in-Fact)	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RIGEL (RIGL) report for David A. Santos?

RIGEL reported that EVP and Chief Commercial Officer David A. Santos received a performance-based stock option for 7,394 shares. The option became fully vested on June 17, 2026 once the company determined the required performance metric had been satisfied.

What is the exercise price of David A. Santos’s RIGEL stock option?

The exercise price of David A. Santos’s stock option is $22.49 per share. This price equals the closing price of RIGEL’s common stock on Nasdaq on January 29, 2025, the original grant date of the performance-based award.

When does David A. Santos’s RIGEL performance-based option expire?

David A. Santos’s performance-based stock option expires on January 29, 2035. This provides a long exercise window following its full vesting on June 17, 2026, when RIGEL determined that the specified performance metric had been achieved.

Why was David A. Santos’s RIGEL option reported now under Section 16?

The option was reported once its performance condition was met on June 17, 2026. Because vesting depended on a performance metric, the grant was not reportable under Section 16 until RIGEL determined that metric had been satisfied, triggering full vesting.

Is David A. Santos’s RIGEL transaction an open-market stock purchase or sale?

No, the transaction is a grant of a performance-based stock option, not an open-market trade. It represents equity compensation awarded by RIGEL, with 7,394 underlying shares at a $22.49 exercise price and full vesting once the performance metric was met.